Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509452 | 0.82 | NOS1 (0.38) | ALDH1A1LMNARAB9ANOS1METAP2 | |
| SCHEMBL1284461 | 0.82 | NPSR1 (0.58) | ALDH1A1SMN1; SMN2L3MBTL1LMNARAB9A | |
| SCHEMBL23619188 | 0.81 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2L3MBTL1SCN10AKCNH2 | |
| SCHEMBL10005347 | 0.80 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2L3MBTL1SCN10AKCNH2 | |
| SCHEMBL846855 | 0.80 | SCN10A (0.58) | ALDH1A1SMN1; SMN2L3MBTL1SCN10AKCNH2 | |
| SCHEMBL4527867 | 0.79 | NPSR1 (0.42) | ALDH1A1SMN1; SMN2NOS1METAP2CSNK2A1 | |
| SCHEMBL7028984 | 0.79 | KDM4E (0.50) | ALDH1A1SMN1; SMN2L3MBTL1SCN10AKCNH2 | |
| SCHEMBL2732982 | 0.79 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2L3MBTL1SCN10AKCNH2 | |
| SCHEMBL10248397 | 0.79 | SMN1; SMN2 (0.45) | ALDH1A1SMN1; SMN2L3MBTL1SCN10AKCNH2 | |
| SCHEMBL13264167 | 0.79 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2L3MBTL1SCN10AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180162847-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180098987-A1 | PRMT5 Inhibitors and Uses Thereof | Epizyme, Inc. (US) | 2018-04-12 | — | — | US | disclosed |
| EP-3080099-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2018-04-11 | — | — | EP | disclosed |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9745291-B2 | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof | Epizyme, Inc. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-27 | — | — | US | disclosed |
| US-9675614-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9604930-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20170027935-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-02-02 | — | — | US | disclosed |
| US-9365519-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-17 | — | — | US | disclosed |
| US-20150344434-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344433-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150252031-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-09-10 | — | — | US | disclosed |
| US-8993555-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140329794-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252031-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | ALDH1A1 2460/4885SMN1; SMN2 952/4885L3MBTL1 982/4885 |
| US-20180098987-A1 | PRMT5 Inhibitors and Uses Thereof | PRMT5, PRMT1, PRMT6 | ALDH1A1 2460/4885SMN1; SMN2 952/4885L3MBTL1 982/4885 |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ALDH1A1 2353/4885SMN1; SMN2 4707/4885L3MBTL1 2178/4885 |
| US-20150344433-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | PRMT5, PRMT1, PRMT3 | ALDH1A1 2705/4885SMN1; SMN2 1466/4885L3MBTL1 1042/4885 |
| US-20140329794-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | ALDH1A1 2460/4885SMN1; SMN2 952/4885L3MBTL1 982/4885 |
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | ALDH1A1 2426/4885SMN1; SMN2 1018/4885L3MBTL1 942/4885 |
| US-20170027935-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | ALDH1A1 2460/4885SMN1; SMN2 952/4885L3MBTL1 982/4885 |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | ALDH1A1 1890/4885SMN1; SMN2 1715/4885L3MBTL1 1306/4885 |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | ALDH1A1 3825/4885SMN1; SMN2 1442/4885L3MBTL1 802/4885 |
| US-20180162847-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | PRMT5, PRMT1, PRMT3 | ALDH1A1 2705/4885SMN1; SMN2 1466/4885L3MBTL1 1042/4885 |
| US-20150344434-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | ALDH1A1 2021/4885SMN1; SMN2 1613/4885L3MBTL1 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.